We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allograft Fibrosis Following Pediatric Cardiac Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00328185
Recruitment Status : Terminated (unable to gather sufficient data)
First Posted : May 19, 2006
Last Update Posted : March 16, 2012
Sponsor:
Information provided by:

Study Description
Brief Summary:
Transplantation is the preferred method of treating many forms of end-stage organ failure. While short-term results have improved, long-term outcomes remain inadequate. Myocardial fibrosis could potentially have an adverse effect on long-term cardiac function. We wish to study the degree of fibrosis to see if we can predict survival following pediatric heart transplantation.

Condition or disease
Children Who Underwent Heart Transplantation Prior to Age 18 Received Care at Children's Healthcare of Atlanta

  Show Detailed Description

Study Design

Study Type : Observational
Actual Enrollment : 100 participants
Time Perspective: Retrospective
Official Title: Allograft Fibrosis: Its Regulation and Significance Following Pediatric Cardiac Transplantation
Study Start Date : January 2006
Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children who underwent heart transplantation prior to age 18
Criteria

Inclusion Criteria:

  • Children who underwent heart transplantation prior to age 18
  • Followed up at Children's Healthcare of Atlanta

Exclusion Criteria:

  • Children without a transplanted heart
  • Follow-up not at children's Healthcare of Atlanta
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00328185


Locations
United States, Georgia
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30329
Sponsors and Collaborators
Children's Healthcare of Atlanta
Investigators
Principal Investigator: Brian E Kogon, MD Emory University
More Information

ClinicalTrials.gov Identifier: NCT00328185     History of Changes
Other Study ID Numbers: 05-217
First Posted: May 19, 2006    Key Record Dates
Last Update Posted: March 16, 2012
Last Verified: January 2006

Keywords provided by Children's Healthcare of Atlanta:
pediatric
heart disease
orthotopic heart transplantation
allograft fibrosis

Additional relevant MeSH terms:
Fibrosis
Pathologic Processes